Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
2 October 2017 |
Main ID: |
EUCTR2011-003142-41-PL |
Date of registration:
|
17/04/2012 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study to Assess the Efficacy and Safety of Romosozumab Treatment Compared to Alendronate in Postmenopausal Women with Osteoporosis
|
Scientific title:
|
A Multicenter, International, Randomized, Double-blind,
Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis |
Date of first enrolment:
|
30/05/2012 |
Target sample size:
|
4000 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-003142-41 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 3
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Bulgaria
|
Canada
|
Chile
|
Colombia
|
Czech Republic
|
Denmark
|
Dominican Republic
|
Estonia
|
Finland
|
France
|
Germany
|
Greece
|
Guatemala
|
Hong Kong
|
Hungary
|
Ireland
|
Israel
|
Italy
|
Latvia
|
Lithuania
|
Mexico
|
Netherlands
|
New Zealand
|
Norway
|
Peru
|
Poland
|
Romania
|
Russian Federation
|
Slovakia
|
South Africa
|
Spain
|
Sweden
|
Turkey
|
Ukraine
|
United Kingdom
|
United States
| | | | | | | |
Contacts
|
Name:
|
IHQ-Medical Info - Clinical Trials
|
Address:
|
Dammstrasse 23, P.O Box 1557
CH-6300
Zug
Switzerland |
Telephone:
|
|
Email:
|
MedinfoInternational@amgen.com |
Affiliation:
|
Amgen (Europe) GmbH |
|
Name:
|
IHQ-Medical Info - Clinical Trials
|
Address:
|
Dammstrasse 23, P.O Box 1557
CH-6300
Zug
Switzerland |
Telephone:
|
|
Email:
|
MedinfoInternational@amgen.com |
Affiliation:
|
Amgen (Europe) GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 4.1.1 Ambulatory postmenopausal women, age = 55 to = 90 years at randomization. Postmenopausal status is defined as no vaginal bleeding or spotting for 12 consecutive months prior to screening.
4.1.2 Subject meets at least one of the following BDM and fracture criteria
BMD T-score = -2.50 at the total hip or femoral neck AND EITHER at least one moderate (SQ2) or severe (SQ3) verterbral fracture OR at least 2 mild (SQ1) vertebral fractures
or
BDM T-score = -2.00 at the total hip r femoral nec AND EITHER at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR a fracture of the proximal femur that occured within 3 to 24 months prior to randomization
BDM T-score at the time of screening will be assessed by the central imaging vendor based on DXA scans and using data for Caucasian women from the National Health and Nutritional Examination Survey [NHANES] 1998.
Vertebral fractures at the time of screening will be assessed by the central imaging vendor based on lateral spine x-rays.
History of proximal femur fracture will be assessed by the principal investigator based on discharged summary, radiology report, or comparable documentation of type and date of fracture.
4.1.3 At least one hip is evaluable by DXA, as assessed by the principal investigator
4.1.4 Subject has provided informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 150 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 3850
Exclusion criteria: Strontium ranelate,or fluoride (for osteoporosis): more than 1 month of cumulative use within 5 years prior to randomization
IV bisphosphonates
•Zoledronic acid:-any dose received within 3 years prior to randomization-more than 1 dose received within 5 years prior to randomization•IV ibandronate or IV pamidronate:-any dose received within 12 months prior to randomization-more than 3 years of cumulative use, unless last dose received = 5 years prior to randomization
Oral bisphosphonates:•More than 3 years of cumulative use, unless last dose received = 5
years prior to randomization•Any dose received within 3 months prior to randomization
•More than 1 month of cumulative use between 3 and 12 months prior to
randomization. Denosumab or any cathepsin K inhibitor,such as odanacatib:any dose
received within 18 months prior to randomization
Teriparatide or any PTH analogs:•any dose received within 3 months prior to randomization
•more than 1 month of cumulative use between 3 and 12 months prior
to randomization
Systemic oral or transdermal estrogen or SERMs:more than 1 month of
cumulative use within 6 months prior to randomization
Hormonal ablation therapy: more than 1 month of cumulative use within 6 months prior to randomization
Tibolone, cinacalcet or calcitonin:any dose received within 3 months
prior to randomization
Systemic glucocorticosteroids: = 5 mg prednisone equivalent per day for
more than 14 days within 3 months prior to randomization
History of metabolic or bone disease (except osteoporosis) that may
interfere with the interpretation of the results, such as sclerosteosis,
Paget's disease, osteomalacia, osteogenesis imperfecta, osteopetrosis,
ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and
malabsorption syndrome
History of solid organ or bone marrow transplants
-25(OH) vitamin D levels <20 ng/mL as assessed by the central
laboratory.Current hyper- or hypocalcemia, defined as albumin-adjusted serum
calcium outside the normal range, as assessed by the central laboratory.
Serum calcium levels may be retested once in case of an elevated serum
calcium level within 1.1x the ULN as assessed by the central laboratory.
Current, uncontrolled hyper- or hypothyroidism, per subject report or
chart review. Uncontrolled hyperthyroidism is defined as TSH and T4
outside the normal range. Uncontrolled hypothyroidism is defined as
TSH>10.Current, uncontrolled hyperparathyroidism or history of
hypoparathyroidism, per subject report or chart review. Uncontrolled
hyperparathyroidism is defined as: PTH outside the normal range in
subjects with concurrent hypercalcemia; or PTH values >20% above the
ULN in normocalcemic subjects
Possible diagnosis of multiple myeloma or related lymphoproliferative
disorder, as assessed by serum protein electrophoresis performed by the
local laboratory. Exclusion criteria related to contraindications or possible signs of
intolerance to ALN; contraindications and potential signs of intolerance
for ALN therapy include: •Hypocalcemia•Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia •Inability to stand or sit upright for at least 30 min•Hypersensitivity to ALN or other constituents of ALN tablets•Pregnancy and lactation•Other contraindications to ALN based on the country-specific product
insert applicable to the specific study center•Significantly impaired renal function.
General•Subject is currently enrolled in another
Age minimum:
Age maximum:
Gender:
Female: yes Male: no
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Body processes [G] - Bones and nerves physological processes [G11]
|
Postmenopausal osteoporosis MedDRA version: 19.1
Level: PT
Classification code 10031285
Term: Osteoporosis postmenopausal
System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
|
Intervention(s)
|
Product Name: Romosozumab Product Code: AMG785 Pharmaceutical Form: Solution for injection in pre-filled syringe Current Sponsor code: AMG785 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe Route of administration of the placebo: Subcutaneous use
Trade Name: FOSAMAX Product Name: FOSAMAX Pharmaceutical Form: Tablet INN or Proposed INN: ALENDRONATE SODIUM TRIHYDRATE Other descriptive name: ALENDRONATE SODIUM TRIHYDRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 70- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Main Objective: For the primary analysis period (randomization to primary analysis) • To assess the effect of romosozumab treatment for 12 months followed by alendronate (ALN) treatment compared with ALN treatment alone on the subject incidence of clinical fracture (nonvertebral fracture and clinical vertebral fracture) in postmenopausal women with osteoporosis • To assess the effect of romosozumab treatment for 12 months followed by ALN treatment compared with ALN treatment alone on the subject incidence of new vertebral fracture in postmenopausal women with osteoporosis
|
Secondary Objective: Primary analysis period To assess the effect of romosozumab treatment for 12months followed by ALN treatment vs ALN treatment alone on: •Subject incidence of fractures (all fractures [nonvertebral(…)] new… fracture [pelvis(…) hip],(…) fracture and clinical vertebral fracture) 12month double-blind ALN-controlled study period To assess the effect of romosozumab treatment for 12months vs ALN treatment on: •Subject incidence of fractures (clinical fracture [nonvertebral(…)] (…)[nonvertebral(…) fractures] nonvertebral fracture, hip fracture, clinical vertebral fracture, major osteoporotic fracture [hip, forearm, humerus, clinical vertebral]) Overall study period-randomization to end of study To assess the effect of romosozumab treatment for 12months followed by ALN treatment vs ALN treatment alone on subject incidence of hip fracture, major nonvertebral fracture [pelvis, distal femur, proximal tibia, ribs, proximal humerus, forearm and hip](…) See PA5 for complete wording
|
Primary end point(s): During the primary analysis period • Subject incidence of clinical fracture (nonvertebral fracture and clinical vertebral fracture) at primary analysis • Subject incidence of new vertebral fracture through Month 24
|
Timepoint(s) of evaluation of this end point: Month 24
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Month 12 and 24
|
Secondary end point(s): During the primary analysis period
•Subject incidence of nonvertebral fracture at primary analysis
•Subject incidence of all fractures (nonvertebral fracture and new or
worsening vertebral fracture) at primary analysis
•Subject incidence of new or worsening vertebral fracture through
Month 24
•Subject incidence of major nonvertebral fracture (pelvis, distal femur,
proximal tibia, ribs, proximal humerus, forearm, and hip) at primary
analysis
•Subject incidence of hip fracture at primary analysis
•Subject incidence of multiple new or worsening vertebral fractures
through Month 24
•Subject incidence of clinical fracture (nonvertebral fracture and clinical
vertebral fracture) through Month 24
•Subject incidence of nonvertebral fracture through Month 24
•Subject incidence of hip fracture through Month 24
•Subject incidence of clinical vertebral fracture through Month 24
•Percent change from baseline in BMD at the lumbar spine, total hip, and
femoral neck at Months 24 and 36
During the 12-month double-blind ALN-controlled study period
•Subject incidence of clinical fracture (nonvertebral fracture and clinical
vertebral fracture) through Month 12
•Subject incidence of new vertebral fracture through Month 12
•Subject incidence of all fractures (nonvertebral fracture and new or
worsening vertebral fracture) through Month 12
•Subject incidence of nonvertebral fracture through Month 12
•Subject incidence of hip fracture through Month 12
•Subject incidence of major osteoporotic fracture (hip, forearm,
humerus, and clinical vertebral) through Month 12
•Subject incidence of clinical vertebral fracture through Month 12
•Percent change from baseline in BMD at the lumbar spine, total hip and
femoral neck at Month 12
For the overall study period
•Subject incidence of nonvertebral fracture at final analysis (after 440
events)
•Subject incidence of major nonvertebral fracture (pelvis, distal femur,
proximal tibia, ribs, proximal humerus, forearm, and hip) at final
analysis
•Subject incidence of hip fracture at final analysis
|
Secondary ID(s)
|
20110142
|
2011-003142-41-IT
|
Source(s) of Monetary Support
|
UCB Inc
|
Amgen, Inc
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|